United Therapeutics logo

UTHR - United Therapeutics Share Price

$117.44 0.5  0.4%

Last Trade - 10/07/20

Large Cap
Market Cap £4.08bn
Enterprise Value £3.49bn
Revenue £1.14bn
Position in Universe 1062nd / 6345
Unlock UTHR Revenue
Relative Strength (%)
1m -5.51%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -8.51%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
1,289 1,466 1,599 1,725 1,628 1,449 1,369 1,321 +2.4%
+91.5 +34.7 +80.3 -4.5 -1.9 +14.2 -29.1 -9.07
Balance Sheet
FINANCIAL BRIEF: : For the three months ended 31 March 2020, United Therapeutics Corporation revenues decreased 2% to $356.3M. Net income totaled $137.7M vs. loss of $494.6M. Revenues reflect Remodulin segment decrease of 7% to $145.3M, Adcirca segment decrease of 38% to $12.5M, Rest-of-World segment decrease of 11% to $29.6M, United States segment decrease of 1% to $326.7M. Net Income reflects Research and development - other decrease of 16% to $68.6M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for UTHR
Graphical History


UTHR Revenue Unlock UTHR Revenue

Net Income

UTHR Net Income Unlock UTHR Revenue

Normalised EPS

UTHR Normalised EPS Unlock UTHR Revenue

PE Ratio Range

UTHR PE Ratio Range Unlock UTHR Revenue

Dividend Yield Range

UTHR Dividend Yield Range Unlock UTHR Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
UTHR EPS Forecasts Unlock UTHR Revenue
Profile Summary

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). The Company markets and sells an oncology product in the United States, Unituxin (dinutuximab) Injection (Unituxin), which is approved for treatment of neuroblastoma. The Company is also engaged in early-stage research and development of a number of organ transplantation-related technologies.

Last Annual December 31st, 2019
Last Interim March 31st, 2020
Incorporated June 26, 1996
Public Since June 17, 1999
No. of Shareholders: 34
No. of Employees: 920
Sector Healthcare
Industry Biotechnology & Medical Research
Index S&P 400 Mid Cap , Nasdaq Composite , S&P Composite 1500 ,
Exchange NASDAQ Global Select Market
Shares in Issue 44,012,324
Free Float (0.0%)
Eligible for
UTHR Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for UTHR
Upcoming Events for UTHR
Wednesday 29th July, 2020 Estimate
Q2 2020 United Therapeutics Corp Earnings Release
Wednesday 28th October, 2020 Estimate
Q3 2020 United Therapeutics Corp Earnings Release
Frequently Asked Questions for United Therapeutics
What is the United Therapeutics share price?

As of 10/07/20, shares in United Therapeutics are trading at $117.44, giving the company a market capitalisation of £4.08bn. This share price information is delayed by 15 minutes.

How has the United Therapeutics share price performed this year?

Shares in United Therapeutics are currently trading at $117.44 and the price has moved by 47.76% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the United Therapeutics price has moved by 39.83% over the past year.

What are the analyst and broker recommendations for United Therapeutics?

Of the analysts with advisory recommendations for United Therapeutics, there are there are currently 4 "buy" , 2 "hold" and 0 "sell" recommendations. The overall consensus recommendation for United Therapeutics is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will United Therapeutics next release its financial results?

United Therapeutics is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-03-31
What is the United Therapeutics dividend yield?

United Therapeutics does not currently pay a dividend.

Does United Therapeutics pay a dividend?

United Therapeutics does not currently pay a dividend.

When does United Therapeutics next pay dividends?

United Therapeutics does not currently pay a dividend.

How do I buy United Therapeutics shares?

To buy shares in United Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of United Therapeutics?

Shares in United Therapeutics are currently trading at $117.44, giving the company a market capitalisation of £4.08bn.

Where are United Therapeutics shares listed? Where are United Therapeutics shares listed?

Here are the trading details for United Therapeutics:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: UTHR
What kind of share is United Therapeutics?

Based on an overall assessment of its quality, value and momentum, United Therapeutics is currently classified as a Super Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a United Therapeutics share price forecast 2020?

Shares in United Therapeutics are currently priced at $117.44. At that level they are trading at 20.69% discount to the analyst consensus target price of 0.00.

Analysts covering United Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of 11.58 for the next financial year.

How can I tell whether the United Therapeutics share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like United Therapeutics. Over the past six months, the relative strength of its shares against the market has been 41.57%. At the current price of $117.44, shares in United Therapeutics are trading at 18.46% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the United Therapeutics PE Ratio?

The United Therapeutics PE ratio based on its reported earnings over the past 12 months is 9.49. The shares are currently trading at $117.44.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of United Therapeutics?

United Therapeutics's management team is headed by:

Martine Rothblatt - CHM
Paul Mahon - EVP
Raymond Kurzweil - IND
Christopher Patusky - VCH
Christopher Causey - IND
Raymond Dwek - IND
Richard Giltner - IND
Katherine Klein - IND
James Edgemond - CFO
Michael Benkowitz - PRE
Who are the major shareholders of United Therapeutics?

Here are the top five shareholders of United Therapeutics based on the size of their shareholding:

The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 9.41% (4.14m shares)
BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 9.2% (4.05m shares)
Renaissance Technologies LLC Hedge Fund
Percentage owned: 8.16% (3.59m shares)
Fidelity Management & Research Company Investment Advisor
Percentage owned: 5.52% (2.43m shares)
State Street Global Advisors (US) Investment Advisor/Hedge Fund
Percentage owned: 4.35% (1.92m shares)
Similar to UTHR
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.